Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study

Japanese Journal of Clinical Oncology

Volumn 34, Issue 11, 2004, Pages 654-659

  Yoshida, Motoki ^a,h   Ohtsu, Atsushi ^a   Boku, Narikazu ^a   Miyata, Yoshinori ^b   Shirao, Kuniaki ^c   Shimada, Yasuhiro ^c   Hyodo, Ichinosuke ^d   Koizumi, Wasaburo ^e   Kurihara, Minoru ^f   Yoshida, Shigeaki ^a   Yamamoto, Seiichiro ^g  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b Nagano Prefectural Federation of Agricultural Cooperative for Health and Welfare   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^e KITASATO UNIVERSITY HOSPITAL   (Japan)

^f SHOWA UNIVERSITY KOTO TOYOSU HOSPITAL   (Japan)

^g NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^h Dept of Gastroenterology   (Japan)

Author keywords

Chemotherapy; Gastric cancer; Long term survival; Prognostic factors

Indexed keywords

ANTINEOPLASTIC AGENT; CF REGIMEN; CISPLATIN; DOXORUBICIN; DRUG DERIVATIVE; FLUOROURACIL; FTM PROTOCOL; MITOMYCIN;

ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GASTRECTOMY; HUMAN; JAPAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; MULTIVARIATE ANALYSIS; PARAAORTIC LYMPH NODE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROGNOSIS; STOMACH CANCER; SURVIVAL TIME; ADULT; AGED; FEMALE; LYMPH NODE; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; STOMACH TUMOR; SURVIVOR;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DOXORUBICIN; FEMALE; FLUOROURACIL; GASTRECTOMY; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MITOMYCIN; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; STOMACH NEOPLASMS; SURVIVORS;

EID: 16644368878     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyh120     Document Type: Article

References (14)

1. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomized comparison of fluorouracil epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-91.
2. Murad AM, Santiago FF, Petroianu A, Rodrigues MAG, Rauch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41.
3. Glimelius B, Hoffman K, Haglund U, Nyren O, Sjoden PO. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 1994;5:189-90.
4. Scheihauser W, Komek G, Zeh B. Palliative chemotherapy versus supportive care in patients with metastatic gastric cancer: a randomized trial. International Conference on Biology, Prevention and Treatment of GI Malignancy, Cologne, Germany: 68; 1995 (abstract).
5. Kurihara M, Izumi T, Yoshida S, Ohkubo T, Suga S, Kiyohashi A, et al. A cooperative randomized study on tegafur plus mitomycin C versus combined tegafur and uracil plus mitomycin C in the treatment of advanced gastric cancer. Jpn J Cancer Res 1991;82:613-20.
6. Koizumi W, Kurihara M, Sasai T, Yoshida S, Morise K, Imamura A, et al. A phase II study of combination therapy with 5′-deoxy-5-fluorouridine and cisplatin in the treatment of advanced gastric cancer with primary foci. Cancer 1993;172:658-62.
7. Shimada Y, Yoshida S, Ohtsu A, Seki S, Saito H. A phase II study of EAP (etoposide, adriamycin and cisplatin) in the patients with advanced gastric cancer: multi-institutional study. J Jpn Soc Cancer Ther 1991;26:280 (abstract).
8. Ohtsu A, Shimada Y, Yoshida S, Saito H, Seki S, Morise K, et al. Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer. Eur J Cancer 1994;30A:2091-93.
9. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG 9205). J Clin Oncol 2003;21:54-9.
10. Ohkuwa M, Ohtsu A, Boku N, Yoshida S, Miyata Y, Shirao K, et al. Long-term results for patients with unresectable gastric cancer who received chemotherapy in the Japan Clinical Oncology Group (JCOG) trials. Gastric Cancer 2000;3:145-50.
11. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva: World Health Organization 1979.
12. Japanese Research Society for Gastric Cancer. Japanese Classification of Gastric Carcinoma. 1st English edn. Tokyo: Kanehara & Co 1995.
13. Massacesi C, Norman A, Price T, Hill M, Ross P, Cunningham D. A clinical nomogram for predicting long-term survival in advanced colorectal cancer. Eur J Cancer 2000;36:2044-52.
14. Maehara Y, Moriguchi S, Orita H, Kakeji Y, Haraguchi M, Korenaga D, et al. Lower survival rate for patients with carcinoma of the stomach of Borrman type IV after gastric resection. Surg Gynecol Obstet 1992;175:13-6.